Literature DB >> 21674177

Plasma procalcitonin and risk of type 2 diabetes in the general population.

A Abbasi, E Corpeleijn, D Postmus, R T Gansevoort, P E de Jong, R O B Gans, J Struck, H L Hillege, R P Stolk, G Navis, S J L Bakker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21674177     DOI： 10.1007/s00125-011-2216-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome.

Authors:  Ali Abbasi; Eva Corpeleijn; Douwe Postmus; Ron T Gansevoort; Paul E de Jong; Rijk O B Gans; Joachim Struck; Hans L Hillege; Ronald P Stolk; Gerjan Navis; Stephan J L Bakker
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

Review 2.  Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors.

Authors:  K L Becker; E S Nylén; J C White; B Müller; R H Snider
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

3.  Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic beta-cells.

Authors:  A Martínez; S Kapas; M J Miller; Y Ward; F Cuttitta
Journal:  Endocrinology       Date:  2000-01       Impact factor: 4.736

Review 4.  Inflammation, stress, and diabetes.

Authors:  Kathryn E Wellen; Gökhan S Hotamisligil
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

5.  Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA.

Authors:  Nils G Morgenthaler; Joachim Struck; Christina Fischer-Schulz; Elke Seidel-Mueller; Wilfried Beier; Andreas Bergmann
Journal:  Clin Lab       Date:  2002       Impact factor: 1.138

6.  Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis.

Authors:  C C Lee; A I Adler; M S Sandhu; S J Sharp; N G Forouhi; S Erqou; R Luben; S Bingham; K T Khaw; N J Wareham
Journal:  Diabetologia       Date:  2009-03-27       Impact factor: 10.122

7.  Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality.

Authors:  Hiddo J Lambers Heerspink; Auke H Brantsma; Dick de Zeeuw; Stephan J L Bakker; Paul E de Jong; Ron T Gansevoort
Journal:  Am J Epidemiol       Date:  2008-09-05       Impact factor: 4.897

8.  Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR).

Authors:  Beverley Balkau; Céline Lange; Leopold Fezeu; Jean Tichet; Blandine de Lauzon-Guillain; Sebastien Czernichow; Frederic Fumeron; Philippe Froguel; Martine Vaxillaire; Stephane Cauchi; Pierre Ducimetière; Eveline Eschwège
Journal:  Diabetes Care       Date:  2008-08-08       Impact factor: 17.152
  8 in total
  12 in total

Review 1.  Immune regulation of procalcitonin: a biomarker and mediator of infection.

Authors:  G N Matwiyoff; J D Prahl; R J Miller; J J Carmichael; D E Amundson; G Seda; M Daheshia
Journal:  Inflamm Res       Date:  2012-02-22       Impact factor: 4.575

2.  External validation of the KORA S4/F4 prediction models for the risk of developing type 2 diabetes in older adults: the PREVEND study.

Authors:  Ali Abbasi; Eva Corpeleijn; Linda M Peelen; Ron T Gansevoort; Paul E de Jong; Rijk O B Gans; Wolfgang Rathmann; Bernd Kowall; Christine Meisinger; Hans L Hillege; Ronald P Stolk; Gerjan Navis; Joline W J Beulens; Stephan J L Bakker
Journal:  Eur J Epidemiol       Date:  2012-01-04       Impact factor: 8.082

3.  Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.

Authors:  A Abbasi; E Corpeleijn; E Meijer; D Postmus; R T Gansevoort; R O B Gans; J Struck; H L Hillege; R P Stolk; G Navis; S J L Bakker
Journal:  Diabetologia       Date:  2012-04-15       Impact factor: 10.122

4.  Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis.

Authors:  Florian Blanchard; Judith Charbit; Guillaume Van der Meersch; Benjamin Popoff; Adrien Picod; Regis Cohen; Frank Chemouni; Stephane Gaudry; Helene Bihan; Yves Cohen
Journal:  Ann Intensive Care       Date:  2020-05-19       Impact factor: 6.925

5.  Lower Plasma Magnesium, Measured by Nuclear Magnetic Resonance Spectroscopy, is Associated with Increased Risk of Developing Type 2 Diabetes Mellitus in Women: Results from a Dutch Prospective Cohort Study.

Authors:  Joëlle C Schutten; António W Gomes-Neto; Gerjan Navis; Ron T Gansevoort; Robin P F Dullaart; Jenny E Kootstra-Ros; Richard M Danel; Frans Goorman; Rijk O B Gans; Martin H de Borst; Elias J Jeyarajah; Irina Shalaurova; James D Otvos; Margery A Connelly; Stephan J L Bakker
Journal:  J Clin Med       Date:  2019-02-01       Impact factor: 4.241

6.  High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study.

Authors:  Erwin Garcia; Maryse C J Osté; Dennis W Bennett; Elias J Jeyarajah; Irina Shalaurova; Eke G Gruppen; Stanley L Hazen; James D Otvos; Stephan J L Bakker; Robin P F Dullaart; Margery A Connelly
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

7.  HDL Particle Subspecies and Their Association With Incident Type 2 Diabetes: The PREVEND Study.

Authors:  Sara Sokooti; Jose L Flores-Guerrero; Lyanne M Kieneker; Hiddo J L Heerspink; Margery A Connelly; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

8.  Liver function tests and risk prediction of incident type 2 diabetes: evaluation in two independent cohorts.

Authors:  Ali Abbasi; Stephan J L Bakker; Eva Corpeleijn; Daphne L van der A; Ron T Gansevoort; Rijk O B Gans; Linda M Peelen; Yvonne T van der Schouw; Ronald P Stolk; Gerjan Navis; Annemieke M W Spijkerman; Joline W J Beulens
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

9.  Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality.

Authors:  Ali Abbasi; Eva Corpeleijn; Douwe Postmus; Ron T Gansevoort; Paul E de Jong; Rijk O B Gans; Joachim Struck; Janin Schulte; Hans L Hillege; Pim van der Harst; Linda M Peelen; Joline W J Beulens; Ronald P Stolk; Gerjan Navis; Stephan J L Bakker
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

10.  Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.

Authors:  Ali Abbasi; Eva Corpeleijn; Ron T Gansevoort; Rijk O B Gans; Joachim Struck; Janin Schulte; Hans L Hillege; Pim van der Harst; Ronald P Stolk; Gerjan Navis; Stephan J L Bakker
Journal:  Diabetologia       Date:  2014-06-04       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.